



## Sample Information

**Patient Name:** 曾金瀛**Gender:** Male**ID No.:** G120831295**History No.:** 48383251**Age:** 56**Ordering Doctor:** DOC3016D 江起陸**Ordering REQ.:** D6P54P5**Signing in Date:** 2022/05/19**Path No.:** S111-99360**MP No.:** F22048**Assay:** Oncomine Focus Assay**Sample Type:** FFPE**Block No.:** S111-17474D**Percentage of tumor cells:** 40%**Reporting Doctor:** DOC5466K 葉奕成 (Phone: 8#5466)**Note:**

## Sample Cancer Type: Non-Small Cell Lung Cancer

Table of Contents	Page
Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)	2
Biomarker Descriptions	2
Relevant Therapy Summary	3
Relevant Therapy Details	3
Clinical Trials Summary	4
Alert Details	4

### Report Highlights

1 Relevant Biomarkers  
1 Therapies Available  
1 Clinical Trials

## Relevant Non-Small Cell Lung Cancer Variants

Gene	Finding	Gene	Finding
ALK	None detected	NTRK1	None detected
BRAF	None detected	NTRK2	None detected
EGFR	None detected	NTRK3	None detected
ERBB2	None detected	RET	None detected
KRAS	<b>KRAS p.(G12D) c.35G&gt;A</b>	ROS1	None detected
MET	None detected		

## Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
IIC	<b>KRAS p.(G12D) c.35G&gt;A</b> KRAS proto-oncogene, GTPase Allele Frequency: 23.28%	None	cabozantinib	1

Public data sources included in relevant therapies: FDA<sup>1</sup>, NCCN, EMA<sup>2</sup>, ESMO

**Tier Reference:** Li et al. *Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.* J Mol Diagn. 2017 Jan;19(1):4-23.

## Variants (Exclude variant in Taiwan BioBank with >1% allele frequency)

### DNA Sequence Variants

Gene	Amino Acid Change	Coding	Variant ID	Locus	Allele Frequency	Transcript	Variant Effect	Coverage
KRAS	p.(G12D)	c.35G>A	COSM521	chr12:25398284	23.28%	NM_033360.4	missense	1993
ALK	p.(*1621R)	c.4861T>C	.	chr2:29416092	5.04%	NM_004304.5	stoploss	893
FGFR3	p.(N262D)	c.784A>G	.	chr4:1803606	6.67%	NM_000142.4	missense	1995
FGFR1	p.(T726=)	c.2178T>G	.	chr8:38271771	9.13%	NM_001174067.1	synonymous	986
MAP2K1	p.(Y134F)	c.401A>T	.	chr15:66729193	12.15%	NM_002755.4	missense	2000

## Biomarker Descriptions

### KRAS (KRAS proto-oncogene, GTPase)

**Background:** The KRAS proto-oncogene encodes a GTPase that functions in signal transduction and is a member of the RAS superfamily which also includes NRAS and HRAS. RAS proteins mediate the transmission of growth signals from the cell surface to the nucleus via the PI3K/AKT/MTOR and RAS/RAF/MEK/ERK pathways, which regulate cell division, differentiation, and survival<sup>1,2,3</sup>.

**Alterations and prevalence:** Recurrent mutations in RAS oncogenes cause constitutive activation and are found in 20-30% of cancers. KRAS mutations are observed in up to 10-20% of uterine cancer, 30-35% of lung adenocarcinoma and colorectal cancer, and about 60% of pancreatic cancer<sup>4</sup>. The majority of KRAS mutations consist of point mutations occurring at G12, G13, and Q61<sup>4,5,6</sup>. Mutations at A59, K117, and A146 have also been observed but are less frequent<sup>7,8</sup>.

**Potential relevance:** The KRAS inhibitor, sotorasib<sup>9</sup>, is approved (2021) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). The FDA has granted breakthrough therapy designation (2021) to the small molecule inhibitor, adagrasib, for KRAS G12C positive in non-small cell lung cancer following prior systemic therapy<sup>10</sup>. The small molecular inhibitor, RO-5126766, was also granted breakthrough designation (2021) alone for KRAS G12V mutant non-small cell lung cancer or in combination with defactinib, for KRAS mutant endometrial carcinoma and KRAS G12V mutant non-small cell lung cancer<sup>11</sup>. Additionally, onvansertib<sup>12</sup> was granted fast track designation (2020) for second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The EGFR antagonists, cetuximab<sup>13</sup> and panitumumab<sup>14</sup>, are contraindicated for treatment of colorectal cancer patients with KRAS mutations in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146)<sup>8</sup>. Additionally, KRAS mutations are associated with poor prognosis in NSCLC<sup>15</sup>.

## Relevant Therapy Summary

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types
 ☒ No evidence

### KRAS p.(G12D) c.35G>A

Relevant Therapy	FDA	NCCN	EMA	ESMO	Clinical Trials*
cabozantinib	×	×	×	○	×
RMC-4630, pembrolizumab	×	×	×	×	● (I/II)

\* Most advanced phase (IV, III, II/III, II, I/II, I) is shown and multiple clinical trials may be available.

## Relevant Therapy Details

### Current ESMO Information

☒ In this cancer type
 ☐ In other cancer type
 ☒ In this cancer type and other cancer types

ESMO information is current as of 2022-02-28. For the most up-to-date information, search [www.esmo.org](http://www.esmo.org).

### KRAS p.(G12D) c.35G>A

#### ☐ cabozantinib

Cancer type: Thyroid Gland Medullary Carcinoma Variant class: RAS mutation

ESMO Level of Evidence/Grade of Recommendation: II / C

Population segment (Line of therapy):

- Metastatic (First-line therapy)

Reference: ESMO Clinical Practice Guidelines - ESMO-Thyroid Cancer [Annals of Oncology 30: 1856–1883, 2019 doi:10.1093/annonc/mdz400]

## Clinical Trials in Taiwan region:

### Clinical Trials Summary

#### KRAS p.(G12D) c.35G>A

NCT ID	Title	Phase
NCT04418661	A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of SAR442720 in Combination With Pembrolizumab in Patients With Advanced Malignancies	I/II

### Alerts Informed By Public Data Sources

#### Current FDA Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

FDA information is current as of 2022-03-16. For the most up-to-date information, search [www.fda.gov](http://www.fda.gov).

#### KRAS p.(G12D) c.35G>A

#### cetuximab

**Cancer type:** Colorectal Cancer

**Label as of:** 2021-09-24

**Variant class:** KRAS G12 mutation

##### Indications and usage:

Erbix® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of:

##### Head and Neck Cancer

- Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy.
- Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil.
- Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy.

##### Colorectal Cancer

K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by FDA-approved test

- in combination with FOLFIRI for first-line treatment,
- in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy,
- as a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan.

**Limitations of Use:** Erbix® is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown.

##### BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC)

- in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy.

##### Reference:

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/125084s279lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

## KRAS p.(G12D) c.35G>A (continued)

### panitumumab

**Cancer type:** Colorectal Cancer

**Label as of:** 2021-08-25

**Variant class:** KRAS G12 mutation

#### Indications and usage:

VECTIBIX® is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC):

- In combination with FOLFOX for first-line treatment.
- As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
- Limitation of Use: VECTIBIX® is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

#### Reference:

[https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/125147s210lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf)

### defactinib + RO-5126766

**Cancer type:** Endometrial Carcinoma

**Variant class:** KRAS mutation

#### Supporting Statement:

The FDA has granted Breakthrough Designation to the small molecule inhibitor, RO-5126766 alone for KRAS G12V mutant non-small cell lung cancer or in combination with defactinib, for KRAS mutant endometrial carcinoma and KRAS G12V mutant non-small cell lung cancer.

#### Reference:

<https://investor.verastem.com//news-releases/news-release-details/verastem-oncology-receives-breakthrough-therapy-designation-vs>

### bevacizumab + onvansertib + FOLFIRI

**Cancer type:** Colorectal Cancer

**Variant class:** KRAS mutation

#### Supporting Statement:

The FDA has granted Fast Track Designation to the Polo-like Kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab, for KRAS mutations in metastatic colorectal cancer in the second line.

#### Reference:

<https://cardiffoncology.investorroom.com/2020-05-28-Cardiff-Oncology-Announces-Fast-Track-Designation-Granted-by-the-FDA-to-Onvansertib-for-Second-Line-Treatment-of-KRAS-Mutated-Colorectal-Cancer>

## Current NCCN Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

NCCN information is current as of 2022-02-28. For the most up-to-date information, search [www.nccn.org](http://www.nccn.org).  
For NCCN International Adaptations & Translations, search [www.nccn.org/global/international\\_adaptations.aspx](http://www.nccn.org/global/international_adaptations.aspx).

### KRAS p.(G12D) c.35G>A

#### cetuximab

**Cancer type:** Colon Cancer

**Variant class:** KRAS exon 2 mutation

**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab."

**Reference:** NCCN Guidelines® - NCCN-Colon Cancer [Version 1.2022]

#### cetuximab

**Cancer type:** Rectal Cancer

**Variant class:** KRAS exon 2 mutation

**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab."

**Reference:** NCCN Guidelines® - NCCN-Rectal Cancer [Version 1.2022]

#### panitumumab

**Cancer type:** Colon Cancer

**Variant class:** KRAS exon 2 mutation

**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab."

**Reference:** NCCN Guidelines® - NCCN-Colon Cancer [Version 1.2022]

#### panitumumab

**Cancer type:** Rectal Cancer

**Variant class:** KRAS exon 2 mutation

**Summary:**

NCCN Guidelines® include the following supporting statement(s):

- "Patients with any known KRAS mutation (exon 2, 3, 4) or NRAS mutation (exon 2, 3, 4) should not be treated with either cetuximab or panitumumab."

**Reference:** NCCN Guidelines® - NCCN-Rectal Cancer [Version 1.2022]

## Current EMA Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

EMA information is current as of 2022-03-16. For the most up-to-date information, search [www.ema.europa.eu/ema](http://www.ema.europa.eu/ema).

### KRAS p.(G12D) c.35G>A

#### cetuximab, cetuximab + oxaliplatin

Cancer type: Colorectal Cancer

Label as of: 2020-01-30

Variant class: KRAS exon 2 mutation

Reference:

[https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf)

#### panitumumab + oxaliplatin

Cancer type: Colorectal Cancer

Label as of: 2021-12-07

Variant class: KRAS exon 2 mutation

Reference:

[https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf)

## Current ESMO Information

 Contraindicated
  Not recommended
  Resistance
  Breakthrough
  Fast Track

ESMO information is current as of 2022-02-28. For the most up-to-date information, search [www.esmo.org](http://www.esmo.org).

### KRAS p.(G12D) c.35G>A

#### cetuximab

Cancer type: Colorectal Cancer

Variant class: KRAS exon 2 mutation

Summary:

ESMO Clinical Practice Guidelines include the following supporting statement:

- "It has been demonstrated that the (potential) benefit of anti-EGFR antibodies in all treatment lines and either as a single agent or in combination with any chemotherapy regimen is limited to patients in whom a RAS mutation is excluded. It was shown that the 'expanded RAS' analysis (also including the detection of mutations in exons 3 and 4 of the KRAS gene as well as mutations in the NRAS [exons 2-4] gene) is superior to the KRAS (exon 2) analysis in predicting both more efficacy in the expanded RAS wild-type (WT) patients and a potential detrimental effect in patients harbouring any RAS mutation in their tumour genome [II/A]."

Reference: ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2014) 25 (suppl 3): iii1-iii9. (eUpdate: 20 September 2016; Corrigendum: 21 July 2015)]

## KRAS p.(G12D) c.35G>A (continued)

### ⊘ cetuximab + chemotherapy

**Cancer type:** Colorectal Cancer

**Variant class:** KRAS exon 2 mutation

**Summary:**

ESMO Clinical Practice Guidelines include the following supporting statement:

- "It has been demonstrated that the (potential) benefit of anti-EGFR antibodies in all treatment lines and either as a single agent or in combination with any chemotherapy regimen is limited to patients in whom a RAS mutation is excluded. It was shown that the 'expanded RAS' analysis (also including the detection of mutations in exons 3 and 4 of the KRAS gene as well as mutations in the NRAS [exons 2-4] gene) is superior to the KRAS (exon 2) analysis in predicting both more efficacy in the expanded RAS wild-type (WT) patients and a potential detrimental effect in patients harbouring any RAS mutation in their tumour genome [II/A]."
- "Thus, the activity of the anti-EGFR antibodies is confined to RAS WT tumours (and not only KRAS WT tumours). This is true for the combinations of cetuximab or panitumumab alone or with irinotecan- and oxaliplatin-based regimens. Treatment with anti-EGFR antibodies may even harm patients with a RAS mutation, especially when combined with oxaliplatin [I/A]."

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2014) 25 (suppl 3): iii1-iii9. (eUpdate: 20 September 2016; Corrigendum: 21 July 2015)]

### ⊘ panitumumab

**Cancer type:** Colorectal Cancer

**Variant class:** KRAS exon 2 mutation

**Summary:**

ESMO Clinical Practice Guidelines include the following supporting statement:

- "It has been demonstrated that the (potential) benefit of anti-EGFR antibodies in all treatment lines and either as a single agent or in combination with any chemotherapy regimen is limited to patients in whom a RAS mutation is excluded. It was shown that the 'expanded RAS' analysis (also including the detection of mutations in exons 3 and 4 of the KRAS gene as well as mutations in the NRAS [exons 2-4] gene) is superior to the KRAS (exon 2) analysis in predicting both more efficacy in the expanded RAS wild-type (WT) patients and a potential detrimental effect in patients harbouring any RAS mutation in their tumour genome [II/A]."

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2014) 25 (suppl 3): iii1-iii9. (eUpdate: 20 September 2016; Corrigendum: 21 July 2015)]

### ⊘ panitumumab + chemotherapy

**Cancer type:** Colorectal Cancer

**Variant class:** KRAS exon 2 mutation

**Summary:**

ESMO Clinical Practice Guidelines include the following supporting statement:

- "It has been demonstrated that the (potential) benefit of anti-EGFR antibodies in all treatment lines and either as a single agent or in combination with any chemotherapy regimen is limited to patients in whom a RAS mutation is excluded. It was shown that the 'expanded RAS' analysis (also including the detection of mutations in exons 3 and 4 of the KRAS gene as well as mutations in the NRAS [exons 2-4] gene) is superior to the KRAS (exon 2) analysis in predicting both more efficacy in the expanded RAS wild-type (WT) patients and a potential detrimental effect in patients harbouring any RAS mutation in their tumour genome [II/A]."
- "Thus, the activity of the anti-EGFR antibodies is confined to RAS WT tumours (and not only KRAS WT tumours). This is true for the combinations of cetuximab or panitumumab alone or with irinotecan- and oxaliplatin-based regimens. Treatment with anti-EGFR antibodies may even harm patients with a RAS mutation, especially when combined with oxaliplatin [I/A]."

**Reference:** ESMO Clinical Practice Guidelines - ESMO-Metastatic Colorectal Cancer [Ann Oncol (2014) 25 (suppl 3): iii1-iii9. (eUpdate: 20 September 2016; Corrigendum: 21 July 2015)]



## Signatures

Testing Personnel:

Laboratory Supervisor:

Pathologist:

## References

1. Pylayeva-Gupta et al. RAS oncogenes: weaving a tumorigenic web. *Nat. Rev. Cancer*. 2011 Oct 13;11(11):761-74. PMID: 21993244
2. Karnoub et al. Ras oncogenes: split personalities. *Nat. Rev. Mol. Cell Biol.* 2008 Jul;9(7):517-31. PMID: 18568040
3. Scott et al. Therapeutic Approaches to RAS Mutation. *Cancer J.* 2016 May-Jun;22(3):165-74. doi: 10.1097/PPO.000000000000187. PMID: 27341593
4. Weinstein et al. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat. Genet.* 2013 Oct;45(10):1113-20. PMID: 24071849
5. Román et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target. *Mol Cancer*. 2018 Feb 19;17(1):33. doi: 10.1186/s12943-018-0789-x. PMID: 29455666
6. Dinu et al. Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. *J Med Life*. 2014 Oct-Dec;7(4):581-7. PMID: 25713627
7. Cerami et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov*. 2012 May;2(5):401-4. PMID: 22588877
8. Allegra et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. *J. Clin. Oncol.* 2016 Jan 10;34(2):179-85. PMID: 26438111
9. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/214665s000lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214665s000lbl.pdf)
10. <https://ir.mirati.com/press-releases/press-release-details/2021/Mirati-Therapeutics-Adagrasib-Receives-Breakthrough-Therapy-Designation-from-U.S.-Food-and-Drug-Administration-for-Patients-with-Advanced-Non-Small-Cell-Lung-Cancer-Harboring-the-KRAS-G12C-Mutation/default.aspx>
11. <https://investor.verastem.com/news-releases/news-release-details/verastem-oncology-receives-breakthrough-therapy-designation-vs>
12. <https://cardiffoncology.investorroom.com/2020-05-28-Cardiff-Oncology-Announces-Fast-Track-Designation-Granted-by-the-FDA-to-Onvansertib-for-Second-Line-Treatment-of-KRAS-Mutated-Colorectal-Cancer>
13. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/125084s279lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)
14. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/125147s210lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf)
15. Slebos et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. *N. Engl. J. Med.* 1990 Aug 30;323(9):561-5. PMID: 2199829